PDCD1 and hepatocellular carcinoma: Pembrolizumab is another PD-1 inhibitor that was also granted accelerated FDA approval as second-line therapy for advanced HCC based off results reported from the single-arm phase II KEYNOTE-224 clinical trial [9].